论文部分内容阅读
[目的]研究左旋多巴(L-dopa)联合卡巴拉汀治疗对帕金森病(Parkingson＇s disease,PD)患者肌强直及多巴转运体影响.[方法]选择本院收治的早期帕金森患者101例,随机分为对照组(50例)和观察组(51例).对照组患者给予L-dopa进行治疗,观察组给予L-dopa联合卡巴他汀治疗,连续治疗6个月.比较两组PD严重程度、平衡功能、PD级别、临床症状改善时间、多巴胺转运体放射计数及两组患者不良反应发生情况.[结果]治疗后,观察组患者PD严重程度评分UP-DRS(unified Parkingson＇s disease rating scale,UP-DRS)低于对照组患者(P＜0.05);Berg平衡功能评分高于与对照组(P＜0.05);帕金森Hoehn-Yahr分级情况低于对照组患者(P＜0.05);肌强直、静止性震颤及运动迟缓等症状缓解时间低于对照组(P＜0.05);基底节(basal ganglia,BG)与枕叶(occipital lobe,OC)比值均有增加趋势,但对照组发病对侧高于治疗前(P＜0.05);观察组不良反应发生率低于对照组(P＜0.05).[结论]L-dopa联合卡巴拉汀能够减轻PD症状,改善患者平衡能力,降低PD患者不良反应.“,”[Objective]To study the effect of levodopa combined with rivastigmine on myotonia and dopa transporter in patients with Parkinson＇s disease(PD).[Methods] A total of 101 patients with early Parkinson disease treated in our hospital were randomly divided into control group(n ＝50)and observation group(n ＝51).Patients in the control group were treated with levodopa,and patients in the control group were treated with levodopa plus rivastigmine in continuous treatment for 6 months.Parkinson＇s severity,balance function,Parkinson＇s grade,clinical symptom improvement time,dopamine transporter radiation count and adverse re-actions were compared between the two groups.[Results]After treatment,UP-DRS(UP-DRS)in the obser-vation group was lower than that in the control group(P ＜0.05);Berg balance score higher than that of the control group(P ＜0.05);Parkinson＇s Hoehn-Yahr classification was lower than that of the control group(P＜0.05);Myotonic stiffness,resting tremor and bradykinesia were shorter than those in the control group(P＜0.05).The ratio of basal ganglia(BG)to occipital lobe(OC)tended to increase,but the incidence of contra-lateral control group was higher than that before treatment(P ＜0.05).The incidence of adverse reactions in the observation group was lower than that in the control group(P ＜0.05).[Conclusion]Levodopa combined with rivastigmine can alleviate the symptoms of PD,improve the balance ability of patients and reduce the ad-verse reactions in patients with Parkinson＇s disease.